Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KURA vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MESO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

MESO Overall Winner 6-Pillar Tally: KURA 2 – 3 MESO (1 Tie) Matrix Metrics: KURA 3 – 5 MESO

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). KURA carries a Unified Composite Score of 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. MESO 35.5/100 SELL), MESO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -394.3% operating margin) and revenue trajectory (+390.7% vs. +10.1% YoY).
  • Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KURA vs MESO
KURA NASDAQ
Kura Oncology, Inc.
Pharmaceutical Preparations
$7.30
-6.05% 1D
Market Cap $690.9M
TTM Revenue $79M
Forward P/E N/M
Beta / 30D Vol 1.42β · 108% Vol
Unified Composite Score
64.1 / 100 BUY
Tech 63.0 Fund 64.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $8.86 · SMA50: $10.05
MESO NASDAQ Head-to-Head Winner
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (KURA 2 – 3 MESO)

Columns: Metric · KURA · MESO
1. Valuation Multiples KURA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 8.3x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +10.1% +390.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $79M $120M
Market Cap $690.9M $1.7B
3. Profitability & Quality MESO
Gross Margin N/A 80.0%
Operating Margin -394.3% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) -224.8% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$89M -$45M EBITDA
Cash Flow Margin -112.4% -37.1% EBITDA Mgn
Net Cash / Leverage $32M Net Cash $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KURA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 103.8% (20th %ile) 76.8% (37th %ile)
Put/Call OI Skew 1.50x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KURA (3) vs MESO (5)
Institutional Metric KURA MESO Criterion Row Edge
Market Capitalization
Scale
$690.9M $1.7B Larger Scale MESO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+10.1% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
-394.3% -42.6% Higher Margin MESO
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin KURA
Return on Equity (ROE)
Capital Efficiency
-224.8% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
8% ($7–$14) 6% ($12–$22) Stronger Trend KURA
Beta / 30D Volatility
Risk Regime
1.42β · 108% Vol 1.18β · 78% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
64.1 / 100 (BUY) 35.5 / 100 (SELL) Higher Composite KURA
Trailing 12M Revenue (USD)
Operating Scale
$79M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.3x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$89M ($32M Net Cash) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MESO +13.5 pp
KURA: -19.6% · MESO: -6.1%
3M Horizon MESO +15.6 pp
KURA: -40.79% · MESO: -25.19%
6M Horizon MESO +5.83 pp
KURA: -20.65% · MESO: -14.82%
1Y Horizon MESO +15.23 pp
KURA: -31.65% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KURA vs MESO. Trailing 12-month operating profitability (KURA -394.3% vs MESO -42.6%) and valuation multiples (KURA N/M vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KURA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$79M
Gross MarginN/A
Op. Margin-394.3%
ROE / Fwd P/E-224.8% · N/M
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KURA BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 103.8%
IV Percentile 20th %ile
Put/Call OI Skew 1.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $690.9M market capitalization and -394.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KURA vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Mesoblast Limited (MESO) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). KURA carries a Unified Composite Score of 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin), whereas MESO carries 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. MESO 35.5/100 SELL), MESO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-42.6% vs. -394.3% operating margin) and revenue trajectory (+390.7% vs. +10.1% YoY). Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: KURA posts +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, KURA generates $79M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, KURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

KURA screens cheaper on headline valuation multiples. KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.3x EV/Revenue (-112.4% FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KURA (-224.8% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, KURA carries 103.8% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.50x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 108% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.